These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Nephroprotective and clinical potential of statins in dialyzed patients. Rysz J; Aronow WS; Stolarek RS; Hannam S; Mikhailidis DP; Banach M Expert Opin Ther Targets; 2009 May; 13(5):541-50. PubMed ID: 19368496 [TBL] [Abstract][Full Text] [Related]
27. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol. Gotto AM; Farmer JA Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799 [TBL] [Abstract][Full Text] [Related]
28. Management of dyslipidemias in patients with diabetes and chronic kidney disease. Molitch ME Clin J Am Soc Nephrol; 2006 Sep; 1(5):1090-9. PubMed ID: 17699330 [TBL] [Abstract][Full Text] [Related]
29. Are HMG-CoA reductase inhibitors underutilized in dialysis patients? Seliger SL; Stehman-Breen CO Semin Dial; 2003; 16(3):179-85. PubMed ID: 12753674 [TBL] [Abstract][Full Text] [Related]
30. Modulation of heat shock proteins by statins. Forouzanfar F; Butler AE; Banach M; Barreto GE; Sahbekar A Pharmacol Res; 2018 Aug; 134():134-144. PubMed ID: 29935271 [TBL] [Abstract][Full Text] [Related]
31. Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant. Ahmed MH; Khalil AA Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1021-9. PubMed ID: 21060168 [TBL] [Abstract][Full Text] [Related]
32. [Dyslipidemia as a therapeutic target for prevention of cardiovascular events and end-stage renal disease]. Watanabe T Nihon Rinsho; 2008 Sep; 66(9):1761-9. PubMed ID: 18788407 [TBL] [Abstract][Full Text] [Related]
33. Evidence-based statin prescription for cardiovascular protection in renal impairment. Fabbian F; De Giorgi A; Pala M; Tiseo R; Manfredini R; Portaluppi F Clin Exp Nephrol; 2011 Aug; 15(4):456-63. PubMed ID: 21556807 [TBL] [Abstract][Full Text] [Related]
34. Statins in the prevention of cardiovascular events in patients with renal failure. Buemi M; Floccari F; Nostro L; Campo S; Caccamo C; Sturiale A; Aloisi C; Giacobbe MS; Frisina N Cardiovasc Hematol Disord Drug Targets; 2007 Mar; 7(1):7-13. PubMed ID: 17346123 [TBL] [Abstract][Full Text] [Related]
35. Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure. Baber U; Toto RD; de Lemos JA Am Heart J; 2007 Apr; 153(4):471-7. PubMed ID: 17383281 [TBL] [Abstract][Full Text] [Related]
36. Management of dyslipidemia in renal disease and transplantation. Zolezzi M Saudi J Kidney Dis Transpl; 2006 Jun; 17(2):129-36. PubMed ID: 16903617 [No Abstract] [Full Text] [Related]
37. Lipid abnormalities and cardiovascular risk in renal disease. Ritz E; Wanner C J Am Soc Nephrol; 2008 Jun; 19(6):1065-70. PubMed ID: 18369085 [TBL] [Abstract][Full Text] [Related]
38. Dyslipidemia in children with CKD: should we treat with statins? Tullus K Pediatr Nephrol; 2012 Mar; 27(3):357-62. PubMed ID: 21487766 [TBL] [Abstract][Full Text] [Related]
39. The efficacy and safety of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in chronic kidney disease, dialysis, and transplant patients. Olyaei A; Greer E; Delos Santos R; Rueda J Clin J Am Soc Nephrol; 2011 Mar; 6(3):664-78. PubMed ID: 21393488 [TBL] [Abstract][Full Text] [Related]
40. Treatment with statins may be considered in ESRD patients for primary prevention of cardiovascular disease. Manca-di-Villahermosa S; Taccone-Gallucci M; Maccarrone M Kidney Int; 2009 Jun; 75(12):1354-1355. PubMed ID: 19483750 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]